Cargando…

Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis

Febuxostat is potent and well-tolerated in the management of chronic gout. However, its clinical efficacy and safety in the treatment of hyperuricemia in patients with chronic kidney disease (CKD) and in renal transplant recipients have remained to be fully determined. The MEDLINE, EMBASE and Cochra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xuzhong, Liu, Kun, Sun, Qing, Wang, Yunyan, Meng, Junsong, Xu, Zongyuan, Shi, Zhaofei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122173/ https://www.ncbi.nlm.nih.gov/pubmed/30186411 http://dx.doi.org/10.3892/etm.2018.6367

Ejemplares similares

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
por: Sofue, Tadashi, et al.
Publicado: (2014)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Comparison of efficacy and safety between febuxostat and allopurinol in early post‐renal transplant recipients with new onset of hyperuricemia
por: Shen, Xiaoju, et al.
Publicado: (2018)

The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis
por: Liu, Kun, et al.
Publicado: (2017)

Association between TGFB1 genetic polymorphisms and chronic allograft dysfunction: a systematic review and meta-analysis
por: Liu, Kun, et al.
Publicado: (2017)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Tang, Yushang, et al.
Publicado: (2022)

Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis
por: Zheng, Yanqun, et al.
Publicado: (2022)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Prevalence and risk factors of hyperuricemia among kidney transplant recipients
por: Einollahi, B., et al.
Publicado: (2013)

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
por: Kario, Kazuomi, et al.
Publicado: (2021)

Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
por: Omizo, Hiroki, et al.
Publicado: (2020)

Retracted: The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Healthcare Engineering, Journal of
Publicado: (2023)

Single Nucleotide Polymorphisms of IL-33 Gene Correlated with Renal Allograft Fibrosis in Kidney Transplant Recipients
por: Liu, Xuzhong, et al.
Publicado: (2021)

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)
por: Sezai, Akira, et al.
Publicado: (2019)

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study
por: Tang, Honghu, et al.
Publicado: (2022)

Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer
por: Wu, Ziyu, et al.
Publicado: (2015)

Construction of an individualized clinical prognostic index based on ubiquitination-associated lncRNA in clear cell renal cell carcinoma patients
por: Liu, Kun, et al.
Publicado: (2022)

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
por: Kim, Sollip, et al.
Publicado: (2017)

Hyperuricemia, the heart, and the kidneys – to treat or not to treat?
por: Petreski, Tadej, et al.
Publicado: (2020)

Effects of Hyperuricemia on Renal Function of Renal Transplant Recipients: A Systematic Review and Meta-Analysis of Cohort Studies
por: Huang, Yan, et al.
Publicado: (2012)

Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial
por: Mukri, Mohd Noor Azreey, et al.
Publicado: (2018)

Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017
por: Weisshaar, Stefan, et al.
Publicado: (2022)

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
por: Yisireyili, Maimaiti, et al.
Publicado: (2017)

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

Hyperuricemia and chronic kidney disease: to treat or not to treat
por: Piani, Federica, et al.
Publicado: (2021)

Renal Cancer in Recipients of Kidney Transplant
por: Dhakal, Prajwal, et al.
Publicado: (2017)

Prevention of Renal Damage by Treating Hyperuricemia
por: Nickavar, Azar
Publicado: (2013)

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
por: Kusunose, Kenya, et al.
Publicado: (2021)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia
por: Gohda, Tomohito, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lg6jsp2ecktigvufg71015e6bg